ClinicalTrials.gg
CompletedNCT03591146Updated Jul 14, 2021Results posted

Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

A Phase 1/2 interventional study of TLC590 and Naropin in Inguinal Hernia, sponsored by Taiwan Liposome Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-14.

Sponsored by Taiwan Liposome Company · Phase 1/2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Hernia, Inguinal with a site in United States — 9 open to participants now, 20 under way, none of them phase 3. Hernia, Inguinal · United States.

Enrollment
37th of 60
65 · median 100
Started
2018
with 4 others
Phase 1/2
Only one
of the 77
Registered
43rd of 77
by date

Among the 77 studies in Hernia, Inguinal with a site in United States, this one is the 37th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2018, is the only one in phase 1/2, and was the 43rd registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

9 of the 77 studies in Hernia, Inguinal with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Hernia, Inguinal with a site in United States, or all of them as a file.
02

Study summary

Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study to assess the safety, PK, and efficacy of single postsurgical application of TLC590 compared with Naropin®

Read the detailed description

A Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study to assess the safety, PK, and efficacy of single postsurgical application of TLC590 compared with Naropin® via a single infiltrative local administration in adult subjects following inguinal hernia repair surgery.

Approximately 64 evaluable subjects across 4 cohorts. Dose escalation of a single postsurgical administration of TLC590 or Naropin® will be performed. Dose escalation will be determined by review of treatment-related adverse events and all serious adverse events (AEs) by a safety monitoring committee.

03

Conditions studied

  • Inguinal Hernia

Browse trials for

Keywords

  • Postsurgical Pain Management
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Male or female between 18 and 65 years of age.
  3. Scheduled to undergo a primary, unilateral Lichtenstein inguinal hernia repair with mesh, and be able to use the anesthesia regimen.
  4. (ASA) Physical Status Classification of 1 or 2.
  5. Female subjects are eligible only if: not pregnant; not lactating; not planning to become pregnant during the study; commits to the use of an acceptable form of .
  6. Male subjects must be sterile or commit to the use of a reliable method of birth control for the duration of the study until at least 1 week after the administration of blinded study medication.
  7. ≤ 35 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. abnormal clinical laboratory test value.
  2. Evidence of a clinically significant 12-lead .
  3. History or evidence of orthostatic hypotension, syncope or other syncopal attacks.
  4. History or clinical manifestations of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other condition.
  5. History of seizures or are currently taking anticonvulsants.
  6. History of to ropivacaine, any other amide-type local anesthetic, propofol, hydromorphone or oxycodone (or other opioids).
  7. Persistent or recurrent nausea and/or vomiting due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer.
  8. History of severe or post-operative nausea or vomiting deemed clinically significant.
  9. Concurrent painful condition that may require analgesic treatment during the study period.
  10. Have been receiving or have received chronic opioid therapy.
  11. Use of any of the following medications within 5 half-lives or as specified prior to the study surgical procedure:

    Anti- agents such as aspirin therapy within 7 days; clopidogrel within 5 days; Anticoagulants such as warfarin within 5 days; dabigatran etexilate mesylate within 2 days; factor Xa inhibitor within 24 hours; Class III antiarrhythmic drugs (e.g., amiodarone); Strong CYP1A2 inhibitors, such as cimetidine, ciprofloxacin, enoxacin, and fluvoxamine; CYP1A2 substrates, such as theophylline or imipramine; Strong inhibitors such as voriconazole, erythromycin, ketoconazole, or ritonavir; CYP3A4 substrates, such as atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, or tipranavir; , either systemically, inhaled, intranasally, orally, or by intra-articular injection within 14 days before the study surgical procedure (topical corticosteroid is allowed); Non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to the study surgical procedure; Any product within 30 days prior to administration of blinded study medication.

  12. History of alcohol abuse or prescription and/or illicit drug abuse within 2 years.
  13. Current report of alcohol abuse within 6 months.
  14. Positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse.
  15. History of (HIV), , or .
  16. Have had an inguinal hernia repair in the last 3 months before the study surgical procedure or presents with bilateral or recurrent inguinal hernia, other hernia presentations, or hernias with a large scrotal component that would be difficult to reduce surgically.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    TLC590 190mg

    TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.

    Drug: TLC590

  • Experimental
    TLC590 380mg

    TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.

    Drug: TLC590

  • Experimental
    TLC590 570mg

    TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.

    Drug: TLC590

  • Experimental
    TLC590 475mg

    TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.

    Drug: TLC590

  • Active comparator
    Naropin 150mg

    Naropin injection contains ropivacaine hydrochloride (HCl). Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial

    Drug: Naropin

Interventions

  • DrugTLC590

    TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension

    Also known as: TLC590 (Ropivacaine Liposome Injectable Suspension)

  • Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL

    Also known as: Naropin, 0.5% Injectable Solution

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability: Event of SAE and Treatment-related Severe AE

    Event of serious adverse event (SAE) and treatment-related severe adverse event (TRAE)

    Time frame: Screening till 30 days post investigational product (IP) administration, up to 58 days

07

Results

Posted Jul 14, 2021

Participant flow

TLC590 190mg and Naropin 150mg
Participant flow — TLC590 190mg and Naropin 150mg
MilestoneTLC590 190mgTLC590 380mgTLC590 570mgTLC590 475mgNaropin 150mg
Started120004
Completed120003
Not completed00001
Withdrew: Lost to follow-up00001
TLC590 380mg and Naropin 150mg
Participant flow — TLC590 380mg and Naropin 150mg
MilestoneTLC590 190mgTLC590 380mgTLC590 570mgTLC590 475mgNaropin 150mg
Started012005
Completed011004
Not completed01001
Withdrew: Lost to follow-up01000
Withdrew: Withdrawal by subject00001
TLC590 570mg and Naropin 150mg
Participant flow — TLC590 570mg and Naropin 150mg
MilestoneTLC590 190mgTLC590 380mgTLC590 570mgTLC590 475mgNaropin 150mg
Started001204
Completed001103
Not completed00101
Withdrew: Lost to follow-up00101
TLC590 475mg and Naropin 150mg
Participant flow — TLC590 475mg and Naropin 150mg
MilestoneTLC590 190mgTLC590 380mgTLC590 570mgTLC590 475mgNaropin 150mg
Started000124
Completed000124
Not completed00000

Outcome measures

PrimarySafety and Tolerability: Event of SAE and Treatment-related Severe AE

Event of serious adverse event (SAE) and treatment-related severe adverse event (TRAE)

Time frame:
Screening till 30 days post investigational product (IP) administration, up to 58 days
Reported as:
Number · Event
Safety and Tolerability: Event of SAE and Treatment-related Severe AE
EventTLC590 190mgTLC590 380mgTLC570mgTLC590 475mgNaropin
Safety and Tolerability: Event of SAE and Treatment-related Severe AE21222

Adverse events

Collected over 58 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TLC590 190mg0/12 (0%)0/12 (0%)11/12 (91.7%)
TLC590 380mg0/12 (0%)0/12 (0%)8/12 (66.7%)
TL590 570mg0/12 (0%)0/12 (0%)7/12 (58.3%)
TLC590 475mg0/12 (0%)0/12 (0%)10/12 (83.3%)
Naropin 150mg0/16 (0%)0/16 (0%)13/16 (81.3%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventTLC590 190mgTLC590 380mgTL590 570mgTLC590 475mgNaropin 150mg
ConstipationGastrointestinal disorders2/121/123/121/128/16
NauseaGastrointestinal disorders4/122/122/125/127/16
HeadacheNervous system disorders2/120/121/124/123/16
PyrexiaGeneral disorders4/122/120/122/120/16
VomitingGastrointestinal disorders2/122/120/122/125/16
ParaesthesiaNervous system disorders0/120/123/120/120/16
DizzinessNervous system disorders2/122/120/122/121/16
BronchospasmRespiratory, thoracic and mediastinal disorders2/120/120/120/120/16
FallInjury, poisoning and procedural complications0/120/122/120/120/16
Back painMusculoskeletal and connective tissue disorders0/121/120/122/120/16

Baseline characteristics

One subject who was randomized (period 2, Naropin group) did not receive any treatment (withdraw by subject), and was replaced. This subject was not included in any analysis population.

Age, Categorical
Age, Categorical(Participants)TLC590 190mgTLC590 380mgTLC590 570mgTLC590 475mgNaropin 150mgTotal
<=18 years000000
Between 18 and 65 years121212121664
>=65 years000000
Sex: Female, Male
Sex: Female, Male(Participants)TLC590 190mgTLC590 380mgTLC590 570mgTLC590 475mgNaropin 150mgTotal
Female010214
Male121112101560
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TLC590 190mgTLC590 380mgTLC590 570mgTLC590 475mgNaropin 150mgTotal
Hispanic or Latino111212121663
Not Hispanic or Latino100001
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(Participants)TLC590 190mgTLC590 380mgTLC590 570mgTLC590 475mgNaropin 150mgTotal
United States121212121664
Body Mass Index (BMI)
Body Mass Index (BMI)(Participants)TLC590 190mgTLC590 380mgTLC590 570mgTLC590 475mgNaropin 150mgTotal
BMI <=35 kg/m2121212121664
BMI > 35 kg/m2000000
08

Study locations

1 site
  • JBR Clinical Research
    Draper, Utah 84020, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Jan 2019, 5 months.

Results were first posted in Jul 2021, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2018
First posted
Jul 19, 2018
StartActual
Jul 31, 2018
Primary completionActual
Jan 5, 2019
CompletionActual
Jan 14, 2019
Results first posted
Jul 14, 2021
Last update
Jul 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03591146
Lead sponsor
Taiwan Liposome Company
Responsible party
Sponsor
First posted
Jul 19, 2018
Start date
Jul 31, 2018
Primary completion
Jan 5, 2019
Completion
Jan 14, 2019
Results posted
Jul 14, 2021
Last update
Jul 14, 2021

Study contacts

Carl Brown, PhD
study director · Taiwan Liposome Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion